m <sup>6</sup> A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma
Our study illuminates the role of m<sup>6</sup>A-modified EHD1 in tumor immune evasion and immunotherapy responses, thereby offering a novel avenue to potentially enhance immunotherapeutic sensitivity and improve the prognosis for patients with LUAD.
Authors
- Xin Hong (ORCID: https://orcid.org/0000-0002-9671-0116)
- Yuning Zhan (ORCID: https://orcid.org/0000-0002-1554-8082)
- Li Cai (ORCID: https://orcid.org/0000-0001-9666-8926)
- Jin Ren (ORCID: https://orcid.org/0000-0002-1789-3103)
- Jian Huang (ORCID: https://orcid.org/0000-0001-7315-4252)
- Fanglin Tian
- Xin Li (ORCID: https://orcid.org/0000-0003-0566-890X)
- Xin Wang (ORCID: https://orcid.org/0000-0002-4715-4360)
- Ying Xing (ORCID: https://orcid.org/0000-0003-3584-7466)
- Kexin Zhu (ORCID: https://orcid.org/0000-0002-8892-4077)
- Weina Fan (ORCID: https://orcid.org/0000-0003-4683-6121)
- Xiangyu Wang (ORCID: https://orcid.org/0000-0001-8512-953X)
Institutions
- Harbin Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Theranostics (New Zealand) (NZ)
- Fourth Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Cancer Communications
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1002/cac2.70052
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Harbin Medical University
- Harbin Medical University Cancer Hospital
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Heilongjiang Provincial Postdoctoral Science Foundation